The 5 most recent market catalysts affecting $PRME, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 85
Prime Medicine shares are trading higher after the company announced the FDA clearance of its Investigational New Drug application for PM647 in Alpha-1 antitrypsin deficiency.
The FDA Investigational New Drug (IND) clearance for PM647 is a major positive catalyst for Prime Medicine, as it allows the company to proceed with human clinical trials. This sig…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
Prime Medicine announced that the FDA has cleared its Investigational New Drug (IND) application for PM647, an in vivo Prime Editor targeting Alpha-1 Antitrypsin Deficiency (AATD).…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 75
Prime Medicine shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $9 price target.
The initiation of coverage with an 'Outperform' rating and a specific price target from a reputable firm like BMO Capital is a strong positive catalyst for Prime Medicine. This act…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
BMO Capital's initiation of coverage on Prime Medicine with an Outperform rating and a $9 price target is a positive development for the company. Analyst coverage, especially from …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate
Prime Medicine (PRME) released its Q2 earnings, reporting a smaller loss per share than anticipated by analysts, which is a positive sign for cost management and operational effici…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.